Matthew Roden, Aktis Oncology CEO

Lil­ly makes an­oth­er ra­dio­phar­ma move in col­lab­o­ra­tion with Ak­tis On­col­o­gy

Eli Lil­ly is again dip­ping in­to the buzzy area of ra­dio­phar­ma­ceu­ti­cals by way of pri­vate biotech Ak­tis On­col­o­gy.

The phar­ma gi­ant will dish out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.